KYMRIAH Drug Profile

Summary for Tradename: KYMRIAH

High Confidence Patents:	12
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for KYMRIAH

Recent Clinical Trials for KYMRIAH

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University Health Network, Toronto	PHASE1
Southwest Oncology Group	Phase 2
National Cancer Institute (NCI)	Phase 2

See all KYMRIAH clinical trials

Pharmacology for KYMRIAH

Mechanism of Action	CD19 Receptor Interactions
Physiological Effect	Increased T Lymphocyte Activation
Established Pharmacologic Class	CD19-directed Chimeric Antigen Receptor Genetically-modified Autologous T Cells
Chemical Structure	CD19-specific Chimeric Antigen Receptor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KYMRIAH Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KYMRIAH Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2035-04-07	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2036-07-21	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2041-09-15	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2042-05-23	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2030-05-10	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2033-07-10	DrugPatentWatch analysis and company disclosures
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2033-07-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for KYMRIAH Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novartis Pharmaceuticals Corporation	KYMRIAH	tisagenlecleucel	Injection	125646		2040-09-16	Patent claims search

International Patents for KYMRIAH

Country	Patent Number	Estimated Expiration
Spain	3039539
Japan	2024056708
Mexico	2016013239
Poland	3129470
Australia	2017203087
Costa Rica	20220507
South Korea	20240042250

Supplementary Protection Certificates for KYMRIAH

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C02649086/01	Switzerland		PRODUCT NAME: TISAGENLECLEUCEL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66778 18.10.2018
2019007	Norway		PRODUCT NAME: TISAGENLEKLEUCEL; REG. NO/DATE: 20180827
355 4-2019	Slovakia		PRODUCT NAME: TISAGENLEKLEUCEL; REGISTRATION NO/DATE: EU/1/18/1297 20180827
PA2019502,C2649086	Lithuania		PRODUCT NAME: TISAGENLEKLEUCELAS; REGISTRATION NO/DATE: EU/1/18/1297 20180823
SPC/GB19/011	United Kingdom		PRODUCT NAME: TISAGENLECLEUCEL; REGISTERED: UK EU/1/18/1297 (NI) 20180823; UK PLGB 00101/1101 20180823
LUC00104	Luxembourg		PRODUCT NAME: KYMRIAH - TISAGENLECLEUCEL; AUTHORISATION NUMBER AND DATE: EU/1/18/1297 20180827
CR 2019 00006	Denmark		PRODUCT NAME: TISAGENLECLEUCEL; REG. NO/DATE: EU/1/18/1297 20180827

Market Dynamics and Financial Trajectory for the Biologic Drug: KYMRIAH

Last updated: September 23, 2025

Introduction

KYMRIAH (tisagenlecleucel) stands as a pioneering CAR T-cell therapy developed by Novartis, revolutionizing treatment for certain hematologic malignancies. Approved by the FDA in 2017 for pediatric relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL) and subsequently for adult r/r large B-cell lymphoma, KYMRIAH exemplifies transformative innovation within immuno-oncology. As biologics redefine cancer therapy, understanding KYMRIAH’s market dynamics and financial trajectory is vital for industry stakeholders, investors, and healthcare policymakers seeking insight into its commercial potential and innovative impetus.

---

Market Overview and Therapeutic Positioning

KYMRIAH operates within the high-growth segment of cellular immunotherapies, targeting previously untreatable or refractory cancers. The global oncology market continues expanding annually, projected to reach USD 312 billion by 2027, with immunotherapies harboring a significant share due to durable responses and personalised treatment (source: Fortune Business Insights).

KYMRIAH addresses a niche but rapidly expanding segment—relapsed or refractory B-cell malignancies—characterized by unmet clinical needs. The therapy's targeted cytokine receptor T-cells induce remission by engineering a patient’s immune system, offering potential cure in cases unresponsive to chemotherapy or traditional therapies.

---

Market Drivers Influencing KYMRIAH’s Growth

1. Evolving Regulatory Landscape:
Progressive regulatory pathways facilitate accelerated approvals. The FDA granted KYMRIAH Priority Review and Breakthrough Therapy designation, expediting market entry. Similar regulatory incentives in Europe (EU) and Japan enable broader access, boosting patient uptake.

2. Expanding FDA and Global Approvals:
Since its initial approval, KYMRIAH has gained additional indications, including adult large B-cell lymphoma and mantle cell lymphoma, broadening its commercial footprint. Such approvals promote market penetration and revenue growth.

3. Increased Adoption of CAR T-Cell Therapies:
Growing clinician familiarity and positive clinical outcomes promote adoption, especially in specialized cancer centers. The shift from palliative to potentially curative therapies underpins demand.

4. Manufacturing and Supply Chain Developments:
Novartis has expanded manufacturing capacity, establishing centralized production sites and global logistics to meet rising demand, reducing costs and delivery times—key for scalability.

5. Pricing and Reimbursement Policies:
High price points ($375,000 per infusion) reflect the therapy’s innovative nature and manufacturing complexity. Reimbursement negotiations with payers focus on value-based agreements, influencing access and sales.

---

Market Challenges and Constraints

1. Cost and Accessibility Barriers:
KYMRIAH’s high treatment cost limits access, especially in lower-income regions. Reimbursement hurdles complicate widespread adoption, particularly amid varying healthcare policies.

2. Manufacturing Complexity and Scalability:
The personalized nature of CAR T-cell therapies complicates scale-up. Manufacturing delays, production failures, and logistical complexities impact revenue predictability.

3. Safety and Toxicity Concerns:
Cytokine release syndrome (CRS) and neurotoxicity require careful management, potentially limiting off-label use and creating clinical risks.

4. Competition from Emerging Therapies:
Third-generation CAR T-cells and other immunotherapies, including off-the-shelf allogeneic products, threaten KYMRIAH’s market share as the industry advances towards more scalable solutions.

5. Limited Long-term Data:
While early results are promising, long-term durability data remains evolving. Payers and clinicians seek ongoing evidence to justify sustained reimbursement and utilization.

---

Financial Trajectory Analysis

Revenue Growth Patterns
Since its launch, KYMRIAH’s global sales have exhibited consistent growth. In 2021, Novartis reported approximately USD 552 million in annual net sales of KYMRIAH, up significantly from earlier years, supported by increased approvals and expanded indications (source: Novartis Annual Report).

Market Penetration and Revenue Drivers
The initial focus on pediatric ALL provided a niche but lucrative market segment; subsequent expansion into adult B-cell lymphomas has propelled revenue streams. Decentralized distribution centers and strategic collaborations have further enhanced reach.

Pipeline and Pipeline-Driven Revenue Potential
Novartis continues to develop next-generation CAR T-cell therapies and pipeline candidates, including off-the-shelf allogeneic options, potentially scaling revenue significantly over the next decade.

Pricing Strategies and Reimbursement Trends
High price points necessitate value-based pricing frameworks. Novartis emphasizes the therapy’s ability to induce durable remissions, bolstering payer negotiations. Reimbursement success in key markets directly correlates with revenue stability.

Cost Structure and Profitability
Manufacturing costs are substantial, given personalized production. As manufacturing efficiencies improve, gross margins are expected to increase, supporting long-term profitability.

Market Share and Competitive Position
KYMRIAH remains one of the leading CAR T-cell therapies; however, competitors like Gilead’s Yescarta and Bristol-Myers Squibb’s Breyanzi challenge its market dominance. Differentiation through indications, safety profile, and manufacturing efficiency will influence future market share.

---

Future Market Dynamics and Financial Outlook

1. Increasing Indications and Line Extensions
Broader indications, including multiple myeloma and solid tumors (under investigation), could unlock sizeable new markets, scaling revenues further.

2. Off-the-Shelf Alternatives and Innovation
Off-the-shelf allogeneic CAR T therapies promise scalability, reduced costs, and faster administration, potentially disrupting KYMRIAH’s market share. NA-focused innovations, such as non-viral vector methods, aim to streamline manufacturing.

3. Geographical Expansion
Emerging markets and regions with expanding healthcare infrastructure (e.g., China, India, parts of Southeast Asia) will provide fertile ground for KYMRIAH’s growth, given increasing cancer incidence and growing awareness.

4. Long-term Data and Real-World Evidence (RWE)
Accumulating longitudinal data will underpin value propositions, optimize reimbursement, and enhance clinician confidence, driving sustained growth.

5. Pricing and Policy Trends
Health technology assessments (HTAs) and value-based agreements will shape future pricing models. Payers increasingly demand evidence of survival benefit and cost-effectiveness, influencing revenue trajectories.

---

Conclusion

KYMRIAH’s market dynamics hinge on its role as a pioneering CAR T-cell therapy within a burgeoning immuno-oncology landscape. The therapy’s growth trajectory benefits from regulatory support, indication expansion, and technological innovation, counterbalanced by manufacturing challenges, high costs, and emerging competition. Financial prospects remain strong, driven by increasing adoption across expanded indications and geographical markets. The ongoing evolution of the CAR T-cell space suggests KYMRIAH will maintain its significance but must adapt to technological shifts and policy changes to sustain its commercial momentum.

---

Key Takeaways

• Growth Drivers: Expanding indications, increasing clinician adoption, and global regulatory support underpin KYMRIAH’s market expansion.
• Financial Outlook: Rapid revenue growth is projected, with pipeline and indication expansions serving as catalysts.
• Challenges: Manufacturing complexity, high costs, safety concerns, and competitive innovations pose ongoing hurdles.
• Strategic Opportunities: Off-the-shelf allogeneic CAR T therapies and global market penetration can boost future revenues.
• Long-term Viability: Data from ongoing clinical studies and real-world evidence will be crucial in maintaining market leadership and guiding reimbursement strategies.

---

FAQs

Q1: What are the primary indications for KYMRIAH, and are there plans to expand these?
KYMRIAH is approved for pediatric relapsed/refractory ALL and certain adult B-cell lymphomas. Ongoing clinical trials aim to expand its use to multiple myeloma, solid tumors, and other hematologic malignancies.

Q2: How does KYMRIAH’s pricing impact market access?
The high cost (~USD 375,000 per infusion) necessitates strong payer negotiations and value-based reimbursement agreements. Cost-effectiveness analyses influence acceptance and patient access.

Q3: What manufacturing challenges does KYMRIAH face?
Being a personalized therapy, KYMRIAH’s manufacturing involves complex logistics, lengthy production times, and potential delays, limiting scalability.

Q4: How does competition affect KYMRIAH’s market share?
Competitors like Yescarta and Breyanzi threaten its dominance. Innovations such as off-the-shelf allogeneic therapies aim to provide more scalable options, potentially reducing KYMRIAH’s market share over time.

Q5: What is the long-term financial outlook for KYMRIAH?
With indication expansion, technological improvements, and global reach, revenue growth is expected. However, sustained success depends on navigating manufacturing, pricing, and competitive pressures.

---

Sources

1. Novartis Annual Reports and Investor Relations Communications
2. Fortune Business Insights: Oncology Market Report 2022
3. U.S. Food and Drug Administration (FDA) approval and label updates
4. Industry analyses on CAR T-cell therapeutics and healthcare economics